Table 1.
Patient Characteristics
| Characteristic | Placebo (n=104) |
Sunitinib (n=106) |
Total (n = 210) |
|---|---|---|---|
| Age, y | |||
| Mean ± SD | 66.3 ± 9.3 | 63.6 ± 10.0 | 64.9 ± 9.7 |
| Median | 67.0 | 65.0 | 66.0 |
| Q1, Q3 | 58.5, 73.0 | 57.0, 70.0 | 58.0, 72.0 |
| Range | 44.0–89.0 | 25.0–84.0 | 25.0–89.0 |
| Race, n (%) | |||
|
| |||
| White | 85 (81.7%) | 87 (82.1%) | 172 (81.9%) |
| Black | 13 (12.5%) | 18 (17.0%) | 31 (14.8%) |
| Asian | 3 (2.9%) | 0 (0.0%) | 3 (1.4%) |
| Other | 3 (2.9%) | 1 (0.9%) | 4 (1.9%) |
|
| |||
| Sex, n (%) | |||
| Female | 44 (42.3%) | 49 (46.2%) | 93 (44.3%) |
| Male | 60 (57.7%) | 57 (53.8%) | 117 (55.7%) |
|
| |||
| Performance status, n (%) | |||
| 0 | 42 (40.4%) | 40 (37.7%) | 82 (39.0%) |
| 1 | 62 (59.6%) | 66 (62.3%) | 128 (61.0%) |
|
| |||
| Stage, n (%) | |||
| IIIB | 12 (11.5%) | 14 (13.2%) | 26 (12.4%) |
| IV | 92 (88.5%) | 92 (86.8%) | 184 (87.6%) |
|
| |||
| Prior use of bevacizumab, n (%) | |||
| No | 80 (76.9%) | 83 (78.3%) | 163 (77.6%) |
| Yes | 24 (23.1%) | 23 (21.7%) | 47 (22.4%) |
|
| |||
| Histologic type, n (%) | |||
| Adenocarcinoma (including BAC) | 43 (41.3%) | 53 (50.0%) | 96 (45.7%) |
| Squamous cell | 39 (37.5%) | 31 (29.2%) | 70 (33.3%) |
| Undifferentiated NSCLC | 13 (12.5%) | 15 (14.2%) | 28 (13.3%) |
| Large cell | 5 (4.8%) | 4 (3.8%) | 9 (4.3%) |
| Other | 4 (3.8%) | 3 (2.8%) | 7 (3.3%) |
|
| |||
| Smoking history, n (%) | |||
| Nonsmoker | 10 (9.6%) | 5 (4.7%) | 15 (7.1%) |
| Past smoker | 67 (64.4%) | 76 (71.7%) | 143 (68.1%) |
| Current smoker | 27 (26.0%) | 25 (23.6%) | 52 (24.8%) |
Q, quartile.